Table 4.
Exposure to drugs by related pharmacogenes over available prescribing periods
| Available prescribing period | –2 years (2011–2012) | −10 years (2003–2012) | −20 years (1993–2012) | +5 years (2013–2017) | ||||
|---|---|---|---|---|---|---|---|---|
| Gene | n | % | n | % | n | % | n | % |
| CYP2D6 | 202 516 | 30% | 275 145 | 51% | 170 388 | 57% | 87 650 | 43% |
| CYP2C19 | 257 079 | 38% | 285 659 | 53% | 165 780 | 56% | 109 782 | 54% |
| SLCO1B1 | 156 472 | 23% | 168 050 | 31% | 94 681 | 32% | 44 472 | 22% |
| CYP2C9 | 50 250 | 7% | 51 496 | 10% | 31 897 | 11% | 17 717 | 9% |
| HLA‐B | 22 459 | 3% | 26 252 | 5% | 18 253 | 6% | 8773 | 4% |
| VKORC1 | 26 648 | 4% | 28 488 | 5% | 17 983 | 6% | 9094 | 4% |
| CYP4F2 | 26 479 | 4% | 28 395 | 5% | 17 951 | 6% | 9042 | 4% |
| F5 | 883 | 0.1% | 5935 | 1% | 15 909 | 5% | 143 | 0.1% |
| HLA‐A | 5214 | 0.8% | 9079 | 2% | 8090 | 3% | 1849 | 0.9% |
| DPYD | 4198 | 0.6% | 8132 | 2% | 4576 | 1.5% | 3764 | 2% |
| TPMT | 1936 | 0.3% | 2585 | 0.5% | 1829 | 0.6% | 795 | 0.4% |
| CYP3A5 | 997 | 0.2% | 1662 | 0.3% | 887 | 0.3% | 713 | 0.4% |
| IFNL3 | 3 | 0.0% | 5 | 0.0% | 4 | 0.0% | 1 | 0.0% |
| UGT1A1 | 0 | 0.0% | 2 | 0.0% | 0 | 0.0% | 1 | 0.0% |
| CFTR | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| G6PD | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| RARG | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 0.0% |
| SLC28A3 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| UGT1A6 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
Values are number (%) of patients prescribed any drug with drug/dosing guidelines related to individual pharmacogenes over available prescribing periods. Pharmacogenes are ranked from most to least commonly associated with a prescribed drug over the −20 year prescribing period.